Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis
ABSTRACT Background Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality, and many high‐risk patients fail to reach LDL‐cholesterol (LDL‐C) targets on statins alone. Evolocumab, a PCSK9 inhibitor, offers potent LDL‐C lowering, but a synthesis of its lipid and clinical benefits in seconda...